| Theme | Lynch Syndrome and Hereditary Polyposis Syndromes | |
|---|---|---|
| Title | Anti—PD—1 Antibody Therapy for Mismatch Repair—deficient Tumor | |
| Publish Date | 2019/06 | |
| Author | Kiwamu Akagi | Department of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center |
| [ Summary ] | Pembrolizumab has been approved for unresectable or locally advanced microsatellite instability (MSI)‒high solid cancer that has already been treated by standard therapies. It is the first time in Japan that the indication of a drug is decided by one biomarker regardless of the type of solid tumor. This suggests the direction of the future of cancer medicine. High efficacy is expected in this therapy; meanwhile, we must resolve problems such as the timing of MSI tests and care for patients with Lynch syndrome as soon as possible. | |